Editorial. Comments on the medical management of secondary hyperparathyroidism in the U.S. Use of phosphate-binding medications to limit phosphorus retention and control serum phosphorus levels; Risk factors associated with surgical parathyroidectomy; Decline in parathyroidectomy rates; Role of vitamin D as a modifier of disease progression.